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Background: Families of children living with a rare disease report significant health and social burden, however,
few studies have systematically examined family needs by using validated tools to assess the scope and extent of
this burden. Our aim was to develop a comprehensive survey to assess health, psychosocial and financial impacts
on Australian families caring for a child with a rare disease.
Methods: We developed a self-administered survey for parents/carers incorporating pre-validated tools. The survey
included questions about experiences of diagnosis, health services use and needs, needs for peer and financial
supports. Forty-seven families attending the state-wide Genetic Metabolic Disorders Service at the Children’s
Hospital at Westmead, Sydney were invited to participate.
Results: Of 46 families who received the survey, 30 (65%) completed it. Most (93%) found the survey acceptable
and relevant (91%). Patients were 1–17 years old, 14 (47%) male, and 12 (40%) non-Caucasian. Eighteen (60%) had a
lysosomal storage disease and 12(40%) had a mitochondrial disorder. Eleven (38%) saw 3–5 doctors and four (14%)
saw 6–10 doctors before receiving the correct diagnosis; 43% felt diagnosis was delayed. Four (13%) were
dissatisfied with the way diagnosis was given, due to insensitive style of communication, inadequate information
and psychological support. Psychosocial impact was moderate to high for 90% of families and the level of impact
was not dependent on the level of health functioning of the child. Twenty-six (87%) wanted, but only 13(43%)
received, information about peer-support groups. The 30 children accounted for 168 visits to general practitioners
and 260 visits to specialist doctors; 21 (70%) children had at least one admission to hospital, including one who had
16 admissions in the previous 12 months. Most families (77%) received financial assistance but 52% believed this
was insufficient. Families benefited from a specialised multi-disciplinary clinic but called for patient-held electronic
medical records.
Conclusions: Australian families caring for children with genetic metabolic disorders are adversely impacted by
delays in diagnosis, lack of easy access to peer support groups and lack of psychological support. Further research
is needed to estimate economic impact and to analyse health service delivery models for children with rare
diseases in Australia.
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Families living with rare diseases have traditionally
received little attention from health authorities, clini-
cians and researchers. Rare diseases are difficult to diag-
nose and treat and there is often a lack of appropriate
health services, skilled health professionals and effective
treatment options [1]. Many rare diseases are chronic
and complex and associated with physical, intellectual or
neurological disabilities. As a result, the psychosocial
and emotional impacts are significant for patients and
families, and often compounded by a lack of appropriate
peer and community support services [2]. These impacts
on families have not been systematically explored or
recorded in Australia [1,3]. An evidence base is needed
to support the development of health and social policy,
new health service models and peer-support groups
and to underpin a coordinated National Plan for Rare
Diseases [3].
The definition of a rare disease varies but in Europe it
is accepted as any disease with a population prevalence
of <1/2000 [2,4]. There are between 6000 and 8000 rare
genetic diseases, in addition to rare non-genetic condi-
tions, and when combined they affect approximately 6-10%
of the population [2]. Extrapolating to the Australian
population of 22.5 million, this equates to up to 2.2 mil-
lion Australians, including up to 400,000 children [5].
The impacts of rare diseases on patients and families
have been studied in Europe, United Kingdom and in
the USA. Such studies have often been led by national
organisations representing patients living with a rare dis-
ease, including the National Organization for Rare Dis-
orders (NORD), Rare Diseases UK (RDUK) and the
European Organisation for Rare Diseases (EURORDIS)
[6-8]. These surveys highlighted diagnostic delays, many
patients experiencing rejection by health professionals,
and significant financial and social impacts on families
[8]. However, few of these surveys have used psychomet-
rically validated tools. Smaller studies have been con-
ducted in Australia to investigate the burden of rare
disease, but these have been limited to single disease
groups [9,10]. Studies abroad have highlighted the add-
itional difficulties that can be experienced by children
and adolescents suffering from a rare or chronic disease,
including problems with school functioning, self esteem
and social interaction [11]. Australia requires wide-
ranging data on the impacts of rare diseases using a survey
appropriate for the Australian health care setting to in-
form the development of improved health care and sup-
port services for young patients and their families.
Our aim was to develop a comprehensive survey that
includes validated patient-reported outcome tools appro-
priate for the Australian setting, which would enable
systematic assessment of the impacts of rare diseases on
children and their families and could be applied acrossbroad disease groups. We describe the development of a
new survey and the outcomes of a pilot study in Australian
families who have a child with a genetic metabolic
disorder.
Methods
Development of the survey
We used the World Health Organisation’s framework
for International Classification of Functioning and
Health (ICF) to support the development of a new sur-
vey tool to identify and investigate important topics for
patients and families with rare diseases [12]. The ICF
provides a broad multifactorial, multidisciplinary frame-
work reflecting the diverse and interrelated determinants
of health, and can be applied to the study of any chronic
condition including rare diseases [12]. From the existing
literature, we identified key areas for inclusion in our
survey, which were both significant for patients and fam-
ilies as well as important for health authorities and ser-
vice provision planning. These were broadly categorised
into the following sections:
• Demographics
• Experience of diagnosis
• Health related function of the patient
• Impact on the family
• Use of health services
• Use of support services
A literature review was performed to identify existing
questionnaires and psychometrically validated tools that
could be included in the new survey and would fit our
goals and outcomes in accordance with patient-reported
outcome assessment use models [13]. We selected tools
that were:
• relevant to a paediatric population
• generic (not diseases-specific)
• self-administered either in paper or on-line formats
• simple for parents to complete
• easy to score and analyse.
Interview-based tools were automatically excluded.
Three validated and suitable tools were identified: the
Health Utilities Index Mark II (HUI- II) (assessing health
functioning) [14]; the Impact on Family scale (IOF) [15];
and the Royal Alexandra Hospital for Children Measure
of Function (RAHC MOF) [16]. The HUI-II is validated
for children aged 5 years or more while the RAHC MOF
is validated for all paediatric/adolescent age groups
[14,16]. The RAHC MOF was developed in an Australian
paediatric hospital as a global measure of health and is
designed to be completed by either a medical professional
or parent to categorise health functioning of the child. A
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stant supervision, high medical dependency) is then allo-
cated (Table 1) [16]. The IOF scale is a 24-item tool using
a 4-point Likert scale (strongly agree to strongly disagree)
to score the level of agreement with each of the 24 state-
ments. Each item in the IOF has been tested for reliability
and psychometric validity [15]. The total score for the IOF
is based on 15 out of the 24 items and ranges from 15
(low impact on the family), to 60 (very significant impact
on the family), while a score of 30 indicates moderate
impact [15]. The HUI-II, the RAHC MOF and the IOF
were included in our final survey in their entirety to pre-
serve the psychometric validity and to enable interpret-
ation of scores for each of these instruments.
The EurordisCare surveys [2,8] and the Australian Rett
Syndrome survey [10] were also assessed and questions
on economic impacts, experiences of diagnosis, and use
of support groups were adapted from these surveys and
included in ours. A small number of additional questions
about the use of and need for health services, participa-
tion in research and need for peer support groups were
constructed by us, using multi-item Likert scale answer
formats. These additional questions were simple and
asked for factual information (eg. number of visits to
specialists in the last 12 months) or for opinion (eg.Table 1 Categories and descriptions of the RAHC MOF scale [
Category Description
1. Superior No symptoms; physical
extra-curricular activitie
problems never get ou
2. Good in all areas Virtually no symptoms;
leisure activities; schoo
lived and only occasion
3. No more than slight problems Some significant sympt
term or little interferen
preschool may be sligh
4. Some difficulty in a single area but generally
pretty well
Mild symptoms which
child from doing most
minor effect on mobilit
problems may persist b
5. Variable problems in some but not all areas Moderate symptoms h
mobility; school/presch
may seem O.K.; mainly
6. Severe problems in one area OR moderate
problems in most areas
Severe symptoms havin
leisure activities are affe
maintained; learning di
specialist.
7. Major problems in several areas AND unable to




8. Unable to function in almost all areas Very severe symptoms;
school/preschool; may
9. Needs nursing supervision Confined to bed; in ho
a child the same age c
10. Needs constant supervision High (24 hrs) medical dHow interested are you in finding and utilising support
groups and organisations?). The additional questions
were not psychometrically tested. The first draft of our
survey was reviewed by researchers and clinicians work-
ing in the field of rare diseases. The subsequent draft
was reviewed by 5 lay people and feedback on question
structure and clarity was incorporated into the final
version.
The final survey was 10 pages long and contained 7
sections covering demographics, experiences of diagno-
sis, health related functioning of the child, use of and
needs for health services, impact on family, and use of
and need for financial and social support services.
Health services use was categorised into hospital admis-
sions (defined as a stay in hospital of ≥8 hours), visits to
outpatient clinics and visits to the emergency depart-
ment. The survey was produced in hard copy and also
formatted for on-line completion using the LimeSurvey
program [17].
We piloted the survey by inviting 47 families currently
engaged with the Genetic Metabolic Disorders Service at
The Children’s Hospital at Westmead, in Sydney, Australia
to participate. This state-wide clinic manages a diverse
range of metabolic disorders, including children with
mitochondrial and lysosomal storage disorders. Children16]
ly able; excellent relationships with family and friends; wide range of
s; doing well at school/preschool; developing normally; everyday
t of hand.
usually copes well; physically able; good relationships; normal play &
l/preschool OK; may have problems when stressed but these are short
ally get out of hand.
oms, only briefly get out of hand; sometimes child gets distressed; short
ce with mobility or relationships or play & leisure activities; school/
tly affected or affected for a short time.
recover quickly with treatment; any distress or disability does not stop
things at that age; some anxiety or irritability or brief mood changes;
y or school/preschool or relationships or play & leisure activities;
ut may only be recognized by those who know the child.
ave significant disabling effect on child; minor to moderate effect on
ool may be affected; may need special education; in some situations
managed in outpatient clinic or family doctor.
g a major effect on child’s life; restricted mobility; relationships or play &
cted; child is distressed or has difficult behavior; some relationships are
fficulties or problems with or missing school; likely to have been seen by
t symptoms; child is distressed, withdrawn or has strange or aggressive
mitations on mobility or school/preschool or relationships or play &
list management needed.
child is very distressed; likely to be confined to bed; unable to go to
be in hospital but child is not entirely dependent on others.
spital; very severe symptoms but stable; needs help with self-care which
an do without help.
ependence e.g. In intensive care unit; life-threatening symptoms.






















Has at least one sibling 25(83)
Other family members affected by the same rare disease 12(40)
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they represent a range of phenotypes and a broad
spectrum of health status and functioning.
The 47 families were sent a letter of invitation, an in-
struction sheet, the survey, a reply-paid envelope and a
brief evaluation form asking about the acceptability of
the survey, including its length and content. Families
were asked to complete the questionnaire either on-line
or to return the completed paper version by reply-paid
post. A reminder letter was sent after two weeks. Data
from both the paper and online versions were entered
onto the Statistical Package for the Social Sciences
(SPSS) and analysed using descriptive statistics. Ethical
approval was granted by the Children’s Hospital at
Westmead Human Research Ethics Committee (10/CHW/75).
Results
Sample characteristics
One of the 47 families had changed address and did not
receive the survey. Of the 46 families who received the
survey, 30 (65%) returned the survey. Only two chose to
complete the survey on-line. In the majority (80%) the
child’s mother completed the survey. Among the chil-
dren, approximately half were male, most were less than
10 years of age and 12(40%) identified with an ethnicity
other than Caucasian (Table 1). Eighteen (60%) children
had a lysosomal storage disorder including one of the
Mucopolysaccharidoses (n = 12), Fabry Disease (n = 5),
and Pompe Disease (n = 1). Twelve (40%) children had a
mitochondrial disorder, including mitochondrial respira-
tory chain disorders with various defects (n = 5), Mito-
chondrial Encephalopathy with Lactic Acidosis and
Stroke-like episodes (MELAS) (n = 3), Kearns-Sayre syn-
drome (n = 2), Pearson Syndrome (n = 1) and Leigh syn-
drome (n = 1) (Table 1).
Twenty-five (83%) of the children had siblings and 8 of
the siblings had the same disorder including 5 siblings
who had died from the disorder. The other three siblings
who had the same disorder were older than 18 years and
no longer attached to the Genetic Metabolic Disorders
Service at the Children’s Hospital at Westmead (Table 2).
Experiences of diagnosis
Only one child, whose parent had been diagnosed with
the same disorder, was diagnosed before birth. Two (7%)
children were diagnosed at birth, 9(30%) before 12
months of age, 9(30%) between 12 months and 3 years
of age, and 9(30%) at 4 years of age or more. The major-
ity (73%) of families reported that symptoms or signs of
the disease began before the age of 4 years. Eleven (38%)
children had seen 3–5 doctors and 4 (14%) children had
seen 6–10 doctors before receiving the correct diagnosis.
Five families (17%) reported that their child had initially
been given a wrong diagnosis. Twelve (43%) believedtheir child’s diagnosis could have been made earlier,
citing reasons such as lack of knowledge by health pro-
fessionals about the disease, and unavailable or delayed
testing.
Twenty-three (77%) families were ‘very satisfied’ or
‘satisfied’ with the way in which they were informed of
their child’s diagnosis, while 3 families were neither sat-
isfied not dissatisfied. The 4(13%) families who were dis-
satisfied with the way the diagnosis was given cited
reasons such as an insensitive style of communication,
no offer of support or counselling, and inadequate
provision of information about the disease (Table 3).
Health-related function
The median score on the RAHC MOF was 4 (some diffi-
culty in a single area). Eleven (37%) children scored 1 or
2 (superior or good in all areas), 3 (10%) scored 3 or 4
(slight problems or some difficulties), 12 (40%) scored 5
or 6 (variable problems in some areas or severe problems
in at least one area), and 4(13%) scored 7 or 8 (major pro-
blems or unable to function in almost all areas). No child
scored 9 or 10 (needs nursing supervision).
One child had a cochlear implant, two used hearing
aids, five had extremely poor mobility (‘unable to control
or use arms or legs’) and eight used a wheelchair.
Table 3 Examples of comments about the way the diagnosis was given to families
Positive comments Negative comments
‘The doctor was very assuring and helpful. . .offered a counsellor and a number to
call if I needed any information no matter how important’
‘I was on my own and I was offered no support or counselling. . .
I was told with what seemed to be no empathy or sensitivity’
‘The doctor was honest and did not find it easy to give such bad news’ ‘Too many people in the room’
‘The haemotologist met with me and my husband alone and invited the geneticist
along as well. They also followed with a letter and some fact sheets explaining the
disease. This helped because it was hard to take it all in.’
‘The paediatrician walked out half-way through the diagnosis’
‘Very satisfied because everyone involved knew what they were saying and doing’ ‘Paediatric ophthalmologist not very sensitive; told us loudly with
their back to our daughter. . . who is old enough to understand.
Then referred to the [Genetic] metabolic clinic at Westmead. . ..’
‘The staff in the genetic clinic were very informative and my husband and I could
ask questions’
Table 4 Visits to medical practitioners and allied health
professionals by the 30 families in the last 12 months















Pain Specialist 4 4









Social Worker 6 33
Dietician 10 28
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30) were asked more detailed questions about health
functioning. Fifteen (68%) of the 22 had pain or discom-
fort, and one child had severe pain not relieved by medi-
cations. Eight (36%) reported impaired abilities in
speech, hearing and communication.
Use of health services
The level of health service use varied among the 30 fam-
ilies. Three families reported visiting hospital more than
50 times over the previous 12 months (for clinics, diag-
nostic or treatment procedures or to attend the emer-
gency department) although nine families had not
visited hospital at all in the past year. Admissions to
hospital in the previous 12 months ranged from none
for 10(33%) families, to 16 for one child. Sixteen (53%)
children reported 1–3 admissions and four (13%)
reported 4 or more admissions.
Families reported using the services of multiple doctors.
General practitioners (GPs) were accessed most often.
Twenty-four children (80%) had visited their GP in the
previous 12 months accounting for a total of 168 visits, an
average of seven visits per child per year (Table 4). Fre-
quently accessed specialists included paediatricians,
geneticists, eye specialists, dentists, neurologists and sur-
geons (Table 4). All 30 children had visited at least one
specialist, including a dentist, accounting for 260 visits
over the previous 12 months, an average of 8 visits per
child per year. Use of allied health professionals including
speech therapists, physiotherapists and occupational
therapists was also high: 24 children visited an allied
health professional at least once, accounting for 268 visits
in the previous 12 months, an average of 11 visits per
child per year (Table 4).
Most (80%) families felt they had adequate access to
health services. Thirteen (43%) identified barriers to acces-
sing services including: distance to travel, need for sibling
care, cost, lack of available services, time lost from work
and lack of referral. Twelve (40%) of the families felt thatthere were no barriers to accessing health services. Four
commented on the long waiting times to see specialist
medical practitioners and other health professionals.
When asked about the role of the GP in their child’s
care, the majority (73%) of families agreed the GP’s role
should be to coordinate services and 73% also agreed
that their GP had adequate knowledge of their child’s
disease. Two-thirds (60%) indicated that they had a



































Measure of Function Category* 
Figure 1 Distribution of the Impact on Family Score by MOF*
level of function scores. * MOF Score definitions: 1- Superior
functioning. 2- Good in all areas. 3- No more than slight problems.
4- Some difficulty in a single area. 5- Variable problems in some
areas. 6- Severe problems in one area or moderate problems in
most areas. 7- Major problems in several areas. 8- Unable to function
in most areas. 9- Needs nursing supervision. 10- Needs
constant supervision.
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accessing health services through a specialised centre
housing coordinated multidisciplinary services (namely
the Genetic Metabolic Disorders Service) improved their
experiences in accessing health care. The great majority
(93%) indicated that an electronic health record contain-
ing all relevant medical history would improve their
experiences of accessing health care.
Although our survey did not include any specific ques-
tions about access to treatment, four families raised
issues around equitable access to treatments, indicating
a perceived lack of access to drugs used overseas but not
approved in Australia.
Impact on family
The median IOF score was 36.5 suggesting a moderate level
of impact of disease on families, however the scores ranged
from 19 to 56 suggesting a very wide range of impacts. Only
3 (10%) families scored < 30 on the IOF (indicating a low
level of impact) while 21(70%) scored between 30 and 45
(indicating significant impact) and 6 families scored 46 or
more (indicating very serious impact). We analysed the re-
lationship between the health function score (RAHC MOF)
and the IOF and found that even families whose children
scored 1 or 2 on the (RAHC MOF) and had superior or
good health function scored over 30 on the IOF, indicating
at least moderate impact on the family (Figure 1).
Most families (77%) were receiving some form of
financial support through government programs such as
the Carer Allowance [18]. However, about half (52%)
indicated that the financial assistance they received was
inadequate to cover their needs and 22(73%) said that
additional income was needed to cover medical expenses
(IOF question 1).
Seventy percent of families indicated that they had be-
come closer because of shared experiences when living
with a child with a rare disease (IOF question 21) and
77% had positive experiences with relatives who were
“understanding and helpful” (IOF question 24).
On a scale of 1 (not stressed most of the time) to 5
(highly stressed most of the time) 23 (76%) families
scored 3 or more and 13(43%) scored 4 or 5, suggesting
a significant level of stress. Seventy per cent of families
felt that their child’s illness resulted in the family seeing
friends and relatives less often than desired (IOF ques-
tion 3) and 77% said it was difficult to find a reliable
person to care for their child (IOF Question 7). Seven
respondents were receiving support from a social
worker, counsellor, psychologist, or psychiatrist.
Support services and information needs
Over a half (57%) of families were ‘interested’ or ‘very
interested’ in being involved with a peer support group
but less than half had found a relevant group in Australiaand 37% had looked for a support group overseas
(Table 5). Information regarding relevant support groups
was provided to 43% of families at diagnosis, but 87%
thought this information should be routinely offered at
the time of diagnosis. Families were interested in keeping
abreast of latest research (90%) and 73% were prepared
for their child to participate in relevant research studies.Relevance and acceptability of the survey
All 30 families completed the survey evaluation. Twenty-
nine (97%) indicated that the survey questions were easy
to understand and 28 (93%) felt that the length of the sur-
vey was acceptable. Most (83%) families thought the ques-
tions were relevant to their experiences and none
indicated that they would like any questions left out. Six
(20%) suggested that some important areas had not been
covered including impacts on siblings and the reactions of
the general community to their child. Most (26, 87%) took
less than one hour to complete the survey, including the 7
(23%) who spoke a language other than English at home.Discussion
Data on the experiences of patients living with a rare dis-
ease are scarce in Australia. Our study addresses this gap
and demonstrates impacts on families and on health ser-
vices in a small, well described group of Australian chil-
dren diagnosed with a genetic metabolic disorder and
attending a state-wide multidisciplinary clinic in Sydney,
New South Wales. To assess impact we developed a com-
prehensive survey, which was judged acceptable and rele-
vant by families living with a child affected by a rare
genetic metabolic disease. Our survey is generic and could
Table 5 Reported needs for information about support groups, diseases and research
Question Number of
responses
Yes No Don’t Know
N (%) N (%) N(%)
Need for Support Groups
Would you like information about support groups at diagnosis? 28 26 (87%) 1 (3%) 1 (3%)
Was support group information provided at diagnosis? 30 13 (43%) 13 (43%) 4 (13%)
Are you interested in being involved with support groups? 29 17 (57%) 10 (33%) 2 (7%)
Have you searched for support groups overseas? 30 11 (37%) 19 (63%) 0
Have you found a support group in Australia specific to your child’s rare disease? 29 13 (43%) 13 (43%) 3 (10%)
Access to information and research
Do you believe you have been provided with adequate information about your child’s
disease?
30 23 (77%) 5 (17%) 2 (7%)
Have you been provided with adequate information about you and your child’s legal and
social rights?
29 11 (37%) 12 (40%) 6 (20%)
Have you been provided with adequate information about financial assistance? 29 13 (43%) 13 (43%) 3 (10%)
Are you interested in being kept informed of current research and clinical trials related to
your child’s disease?
30 27 (90%) 2 (7%) 1 (3%)
Are you interested in your child participating in relevant research studies? 29 22 (73%) 3 (10%) 4 (13%)
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phenotypically diverse range of metabolic diseases repre-
sented by our sample. We propose to study the relevance
of this survey to a wider range of rare diseases in the fu-
ture. Our survey is the first to use validated tools to assess
impact on families and to correlate this with health func-
tioning in the child. Such data are needed to inform future
development of health and support services for families.
This study has some limitations. Our sample was small,
was sourced from a specialised clinic in a tertiary paediat-
ric hospital and included only selected rare disease groups,
thus the findings cannot necessarily be extrapolated to
other patient groups. Nevertheless, the cohort included
65% of all children with lysosomal storage diseases and
mitochondrial diseases from a state-wide service, where
no other such service exists, and is therefore likely to be
representative of families living with these conditions in
NSW and probably throughout Australia. Our response
rate (65%), was high compared with the EurordisCare2
survey (33%) [8], and EurordisCare3 survey (30%) [2]. The
RDUK survey did not report a response rate [7].
Although most children in our study were born in Aus-
tralia and over half were Caucasian, Asian families (17%)
and Middle Eastern families (17%) were over-represented
compared with the reported proportion of these groups
within the general Australian population (7% Asian and
1.4% North African and Middle eastern) [19], indicating a
high burden for these communities, and a need for aware-
ness raising about genetic disorders. Often the child
attending the clinic was not the only affected child in the
family. Eight families reported a sibling who was currently
affected by the same disorder including five families who
had one or more children who had died due to the raredisorder, highlighting the significant and enduring burden
of genetic diseases. Such families may benefit from
improved access to genetic counselling services.
Forty per cent of families believed that their child’s
diagnosis could have been made earlier and many saw
multiple doctors before receiving the correct diagnosis.
These findings echo results from the EurordisCare2 sur-
veys and the RDUK survey [2,7,8]. Delay in diagnosis
can have medical consequences such as delayed treat-
ment, unnecessary tests, and psychological stress for the
family. Our findings indicate a need for better education
of health professionals during undergraduate and post-
graduate studies, better awareness of existing informa-
tion resources and development of new resources to
support clinical care. Such resources could include clin-
ical guidelines on diagnosis and treatment, educational
modules which could be delivered via the internet and
lists of specialised clinics and referral pathways.
The way in which diagnosis was given was satisfactory
for most families and only four were ‘not satisfied’ or
‘very unsatisfied’. This compares favourably to results
from the EurordisCare2 survey, in which 35% of respon-
dents indicated that they were dissatisfied with the way
diagnosis was given [8]. Our sample, however, was very
small and included only families who were already
attached to a multidisciplinary genetic metabolic service.
Families who had negative experiences of receiving the
diagnosis may have received the diagnosis from other
health professionals outside of the Genetic Metabolic
Disorders Service and before being referred to the state-
wide service. Few families in our study were offered
psychological support or counselling at the time of diag-
nosis, despite feeling ‘devastated’, ‘confused’, ‘heart-broken’
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the need for routine psychological support following
diagnosis.
The level of health related functioning among children
with a rare disease can vary widely, however impacts on
mobility, cognitive function, emotional functioning and
day-to-day activities are common [20]. Caring for a child
with a rare condition has a high impact on families even
when the child has relatively mild disease. In our study,
families of children who scored in the “good health func-
tion” range of the (RAHC MOF), scored in the moderate
level of family impact on the IOF, indicating that there
are factors apart from the level of health function of the
child which contribute to the impact on family. Indeed,
an Australian study on stress in mothers and fathers of
children with fragile X syndrome found the strongest
predictors in these families were marital satisfaction (for
mothers) and the child’s adaptive abilities (for fathers)
[10]. Caring for children with a rare disease has been
linked with significant stressors such as the need to
accept the diagnosis and adaptation to new roles,
increased demands on time, and requirement to manage
the child’s day-to-day care [21]. In our study, frequent
burdens for families included little time to see relatives
and friends and difficulties finding a reliable person to
care for their child. High levels of psychological and
financial stress were reported by over 75%.
The high levels of reported stress suggest an unmet
need for psychological support from mental health pro-
fessionals, counsellors or peer support groups, however,
only 7 of the 30 families were receiving support from a
mental health professional and less than half had found
a relevant peer support group. Over a third (37%) had
searched for a support group overseas, suggesting a lack
of availability or access to support groups in Australia.
The importance of support groups is being increasingly
recognised, through their ability to connect to patients
and families via the internet, as well as collaborating
with research groups [22]. Organisations such as the
Association of Genetic Support of Australasia (www.agsa-
geneticsupport.org.au) and Genetic Alliance groups across
Australia act to promote peer support, however peer
support organisations are often poorly resourced and
lack coordination. There is also lack of a coordinated
approach to advocacy for people living with rare dis-
eases in Australia. A newly established organisation,
Rare Voices Australia (www.rarevoices.org.au) aims to
facilitate better access to and coordination of peer sup-
port services and to advocate at the national level for
people living with a rare disease.
Our results illustrate the frequent use of health services
for some children with rare diseases, including 16 admis-
sions for one child and >50 visits to hospital for three chil-
dren in a 12 month period. Given such frequent use ofhealth services, the finding that 80% of families felt they
had adequate access to health services was positive. How-
ever, participants in our study were recruited via a specia-
lised multidisciplinary service and we therefore anticipated
high levels of satisfaction with the provision of health ser-
vices. Nevertheless, families identified key difficulties in
accessing care, including practicalities such as time for
travel to clinic and long waiting times to see specialist doc-
tors and allied health professionals. The latter suggests a
substantial burden for clinics with limited resources and
staff. Service delivery via appropriately resourced specia-
lised centres housing medical practitioners, allied health
staff, pathology, pharmacy and access to equipment and
information in one location and patient held electronic
health records might further improve their experiences
when accessing many different health professionals. Our
survey did not specifically ask whether there were delays
to see staff in the multidisciplinary Genetic Metabolic Ser-
vice or outside of the service, and this will be taken into
consideration when further developing our survey.
We were interested in the role of the general practi-
tioner in the care of children with rare diseases and
complex and highly specialised needs. An article pub-
lished in the Medical Journal of Australia by two GPs
highlighted the lack of a defined role for the GP when
dealing with patients with a rare disease and their fam-
ilies, as well as a lack of available support and resources
for GPs [23]. GPs are in the front line of the health sys-
tem and can empower and advocate for patients living
with a rare disease by coordinating care and making
decisions about appropriate referrals for diagnosis and
treatment as well as providing routine general and pre-
ventative health care such as vaccinations. The majority
of families (73%) thought their GP was in a position to
coordinate the wide range of services their child
required. GPs have called for a systematic, primary-care
approach to rare disease to assist them in managing
patients and families, thereby reducing diagnostic delays,
providing care coordination, and providing an extra
avenue for access to psychological support [23].
Conclusions
Results from this pilot study of 30 Australian families
living with a rare metabolic disease indicate that these
children have significant disability and health needs and
that families are emotionally and financially stressed.
Most suggested that information about the disease,
details about support groups and psychological support
for the family should be routinely offered at the time of
diagnosis. Although all families were accessing health
care via a multidisciplinary clinic they felt that their
experiences could be improved with better coordination
of care and introduction of electronic health records
which could be accessed by the many different health
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such as EURORDIS and NORD, play an important role
in advocating for patients with rare diseases. We believe
that Australian families living with rare disease would
benefit from an overarching national organisation to co-
ordinate advocacy for rare disease strategy and policy in
Australia to improve access to health care and financial
and community support. We have begun a large study
using a revised version of our survey and involving ap-
proximately 500 children living with a variety of rare dis-
eases, to further inform patient needs.
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